期刊文献+

大剂量甲氨蝶呤治疗B细胞淋巴瘤的不良反应及护理要点分析 被引量:3

下载PDF
导出
摘要 目的分析大剂量甲氨蝶呤治疗B细胞淋巴瘤的不良反应及护理要点。方法选取2017年6月—2018年6月在本科接受治疗的93例B细胞淋巴瘤患者为研究对象。所有患者均采用大剂量甲氨蝶呤治疗,观察患者的治疗效果。结果92例患者的治疗均顺利完成,其中完全缓解的有46例(49.46%),部分缓解的有40例(43.01%),治疗总有效率为85.07%。结论采用大剂量甲氨蝶呤治疗B细胞淋巴瘤,应详细观察患者化疗期间出现的各项不良反应,提供针对性护理措施服务,密切关注患者各项生命体征,及时发现,及时处理,做好积极预防工作,帮助患者顺利度过治疗期。
出处 《当代护士(上旬刊)》 2020年第4期89-91,共3页 Modern Nurse
  • 相关文献

参考文献6

二级参考文献76

  • 1谌海兰.利妥昔单克隆抗体联合CHOP方案治疗高龄非霍奇金淋巴瘤患者的疗效[J].中国老年学杂志,2014,34(12):3264-3266. 被引量:9
  • 2吴蓓雯,方琼,朱唯一.肿瘤专科护理[M].北京:人民卫生出版社,2012:90-93. 被引量:7
  • 3Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno- histochemistry using a tissue microarray [ J ]. Blood, 2004, 103(1): 275-282. 被引量:1
  • 4Niitsu N, Okamoto M, Tamaru J, et al. Clinicopathologic charac- teristics and treatment outcome of the addition of rituximab to chemo- therapy for CDS-positive in comparison with CD5-negative diffuse large B-cell lymphoma[ J]. Ann Onct)l, 2010, 21 (10) : 2069 - 2074. 被引量:1
  • 5Li Y, Yimamu M, Wang X, et al. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression [ J ]. Int J hematol, 2014, 99 ( 1 ) : 79 - 86. 被引量:1
  • 6Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[ J]. Blood, 2014, 123 (6) : 837 -842. 被引量:1
  • 7Pfreundschuh M, Kuhnt E, Tramper L, et al. CHOP-like chemo- therapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group [J]. Lancet Oncol, 2011, 12(11): 1013 -1022. 被引量:1
  • 8Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma [ J]. J Clin Oncol, 2008, 26 (28) : 4587 - 4594. 被引量:1
  • 9Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma[J]. Blood, 2013, 121(12): 2253-2263. 被引量:1
  • 10Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy [ J]. Leuk Lymphoma, 2010, 51(1): 161 -163. 被引量:1

共引文献68

同被引文献24

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部